EVO-200 is under clinical development by Evofem Biosciences and currently in Phase I for Bacterial Vaginosis. According to GlobalData, Phase I drugs for Bacterial Vaginosis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EVO-200’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EVO-200 overview

EVO-200 is under development for the prevention of recurrent bacterial vaginosis (BV). The therapeutic candidate is a vaginal pH modulator and is administered as vaginal gel.

Evofem Biosciences overview

Evofem Biosciences (Evofem) carries out the development and commercialization of reproductive and contraceptive care products for women. The company’s pipeline products include phexxi, a hormone-free contraceptive vaginal gel; and EVO200 vaginal gel, to treat recurrent bacterial vaginosis (BV). It uses proprietary multipurpose prevention technology (MPT) vaginal gel candidate for multiple indications which include human immunodeficiency virus (HIV) prevention; contraception; prevention of urogenital transmission of chlamydia trachomatis infection and Neisseria gonorrhea infection in women. Evofem sells its product under the brand name Phexxi. The company markets its product across the globe through partnerships and licensing agreements. Evofem is headquartered in San Diego, California, US.

For a complete picture of EVO-200’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.